In summary, the overexpression of CXCL10, activated CD4 T cells, and M1 macrophages not only reduces the risk of CRC and had a better prognosis but also enhances the efficacy of neoadjuvant therapy, suggesting their might play an essential role in antitumor immunity. This evidence concerns the gene CXCL10 and colorectal carcinoma.